Investigation of the tumor concentrations of the anticancer drug osimertinib in tumor resection material of patients with colorectal cancer.

Primary objectives: To determine the intratumoral concentration of osimertinib in peritoneal metastasis upon 2 weeks of treatment of patients who are candidate for CRS-HIPEC treatment (group 1), and in liver metastasis of patients who are candidate for primary liver resection (group 2). These clinical determined intratumoral osimertinib concentrations will be compared with the effective tissue concentrations in PDTOs from PM of CRC from the PDO-CRPM study.
Primary endpoints: Intratumoral osimertinib concentration in peritoneal metastasis and liver metastasis.